APA (7th ed.) Citation

Lolli, I., Santini, D., Berardi, R., Badalamenti, G., Ibrahim, T., Berruti, A., . . . Pastorelli, D. (2020, July). Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol. BMJ Open.

Chicago Style (17th ed.) Citation

Lolli, Ivan, et al. "Randomised Phase II Trial of CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of Predictive Role of PET/CT Imaging and Biological Markers (SENECA Trial): A Study Protocol." BMJ Open Jul. 2020.

MLA (9th ed.) Citation

Lolli, Ivan, et al. "Randomised Phase II Trial of CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of Predictive Role of PET/CT Imaging and Biological Markers (SENECA Trial): A Study Protocol." BMJ Open, Jul. 2020.